Psoriatic Arthritis: What the Dermatologist Needs to Know, Part 2

López-Ferrer, A.; Torrente-Segarra, V.; Puig, L.

doi:10.1016/S1578-2190(10)70712-5

Article information

Abstract

Bibliography

Download PDF

Statistics

Abstract

This review aims to cover all aspects related to the treatment of psoriatic arthritis and the evaluation of the response to treatment. We define the various evaluation methods currently used to assess response to treatment in patients with psoriatic arthritis and the complementary examination techniques used to ensure adequate follow-up. These tools enable both the dermatologist and the rheumatologist to carry out an ongoing evaluation of the clinical course, severity, and prognosis of the disease. The treatment lines proposed by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and the Spanish Society for Rheumatology are discussed. Emerging strategies for treating this condition and improving prognosis are examined.

Keywords:

Psoriasis

Psoriatic arthritis

Evaluation methods

Treatment

Resumen

En esta revisión se pretenden abarcar todos los aspectos relacionados con el tratamiento de la artritis psoriásica así como la evaluación de la respuesta al tratamiento. Por este motivo, se definen los diferentes métodos de evaluación que se utilizan en la actualidad para valorar la respuesta al tratamiento de los pacientes con artritis psoriásica y las exploraciones complementarias que deben realizarse para el correcto seguimiento de estos pacientes. A través de estas herramientas, tanto el dermatólogo como el reumatólogo pueden evaluar la evolución, gravedad y pronóstico de la enfermedad en cada momento. En relación al tratamiento se exponen las líneas de tratamiento propuestas por la GRAPPA y la Sociedad Española de Reumatología (SER) y se introduce la aparición de nuevas terapias emergentes para el tratamiento de esta enfermedad y la mejora de su pronóstico.

Palabras clave:

Psoriasis

Artritis psoriásica

Métodos de evaluación

Tratamiento

Full text is only aviable in PDF

References

[1.]

P.J. Mease, C.E. Antoni, G.G. Gladman, W.J. Taylor.

Psoriatic arthritis assessment tools in clinical trials.

Ann Rheum Dis, 64 (2005), pp. 49-54

[2.]

J.M. Berthelot, A. Blanchais, T. Marhadour, B. le Goff, Y. Maugars, A. Saraux.

Fluctuations in disease activity scores for inflammatory joint disease in clinical practice: do we need a solution?.

Joint Bone Spine, 76 (2009), pp. 126-128

http://dx.doi.org/10.1016/j.jbspin.2008.12.002 | Medline

[3.]

P.J. Healy, P.S. Helliwell.

Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.

Arthritis Rheum, 59 (2008), pp. 686-691

http://dx.doi.org/10.1002/art.23568 | Medline

[4.]

C.T. Ritchlin, A. Kavanaugh, D. Gladman, P.J. Mease, P. Helliwell, W.H. Boehncke, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), et al.

Treatment recommendations for psoriatic arthritis.

Ann Rheum Dis, 68 (2009), pp. 1387-1394

http://dx.doi.org/10.1136/ard.2008.094946 | Medline

[5.]

P.J. Mease.

Psoriatic arthritis assessment and treatment update.

Curr Opin Rheumatol, 21 (2009), pp. 348-355

http://dx.doi.org/10.1097/BOR.0b013e32832c7832 | Medline

[6.]

E. Collantes, J.L. Fernández Sueiro, R. García-Vicuña, J. Gratacós, J. Mulero, S. Muñoz Fernández, et al.

Actualización del consenso de la Sociedad Española de Reumatolgía sobre el uso de antagonistas del TNF-a en las espondiloartritis, incluida la artritis psoriásica.

Reumatol Clin, 3 (2007), pp. S261-S271

[7.]

L. Puig.

Infliximab: patients selection.

Actas Dermosifiliogr, 99 (2008), pp. 23-29

Medline

[8.]

A. Kavanaugh, I. McInnes, P. Mease, G.G. Krueger, D. Gladman, J. Gómez-Reino, et al.

Golimumab, a new human tumor necrosis factor a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis.

Arthr Rheum, 60 (2009), pp. 976-986

[9.]

J.M. Jackson.

TNF-a inhibitors.

Dermatol Ther, 20 (2007), pp. 251-264

http://dx.doi.org/10.1111/j.1529-8019.2007.00138.x | Medline

[10.]

A.A. Saad, D.P.M. Symons, P.R. Noyce, D.M. Ashcroft.

Risks and benefits of tumor necrosis factor-a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trial.

J Rheumatol, 35 (2008), pp. 883-890

Medline

[11.]

P.J. Mease.

Spondyloarthritis update.

Bull NYU Hosp J Dis, 66 (2008), pp. 203-209

[12.]

L.C. Coates, J. Fransen, P.S. Helliwell.

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

Ann Rheum Dis, 69 (2010), pp. 48-53

http://dx.doi.org/10.1136/ard.2008.102053 | Medline

[13.]